ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

$1 Million Gift to Duke Funds Urologic Research Center.

November 24, 2000

List of FY97 SPORE Grantees and Their Awards

December 12, 1997

In Brief: Knowledge Surgeons, Radiotherapists, Pathologists Untapped, Zubrod Suggests

February 20, 1976

In Brief: ONS Invites Proposals For Research On Hazards Of Chemotherapy; UTSCC Adopts Code Of Ethics

August 31, 1984

Colorectal Cancer Screening Programs Could Cut Future Treatment Costs

September 25, 2009